Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer

NCT04322617 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

1200

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Anlotinib plus the same Immune Checkpoint Inhibitors.
DRUG: Anlotinib plus the new Immune Checkpoint Inhibitors.
DRUG: Anlotinib

Sponsor

Hunan Province Tumor Hospital